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Background: Surgical resection is the only curative treatment for pancreatic and periampullary cancer, but many
patients undergo unnecessary laparotomy because tumours can be understaged by computerised tomography
(CT). A recent Cochrane review found diagnostic laparoscopy can decrease unnecessary laparotomy. We compared
the cost-effectiveness of diagnostic laparoscopy prior to laparotomy versus direct laparotomy in patients with
pancreatic and periampullary cancer with resectable disease based on CT scanning.
Method: Model based cost-utility analysis estimating mean costs and quality-adjusted life years (QALYs) per patient
from the perspective of the UK National Health Service. A decision tree model was constructed using probabilities,
outcomes and cost data from published sources. One-way and probabilistic sensitivity analyses were undertaken.
Results: When laparotomy following diagnostic laparoscopy occurred in a subsequent admission, diagnostic laparoscopy
incurred similar mean costs per patient to direct laparotomy (£7470 versus £7480); diagnostic laparoscopy costs
(£995) were offset by avoiding unnecessary laparotomy costs. Diagnostic laparoscopy produced significantly more
mean QALYs per patient than direct laparotomy (0.346 versus 0.337). Results were sensitive to the accuracy of
diagnostic laparoscopy and the probability that disease was unresectable. Diagnostic laparoscopy had 63 to 66%
probability of being cost-effective at a maximum willingness to pay for a QALY of £20 000 to £30 000. When laparotomy
was undertaken in the same admission as diagnostic laparoscopy the mean cost per patient of diagnostic laparoscopy
increased to £8224.
Conclusions: Diagnostic laparoscopy prior to laparotomy in patients with CT-resectable cancer appears to be
cost-effective in pancreatic cancer (but not in periampullary cancer), when laparotomy following diagnostic
laparoscopy occurs in a subsequent admission.
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Surgical resection is generally considered to be the only
curative treatment for pancreatic and periampullary
cancer (which includes ampullary cancer and duodenal
cancer along with cancer of the head of the pancreas).
Only 15 to 20% of patients undergo potentially curative
resection [1-5]. In the remaining patients, the tumours are
not resectable because the cancer has spread into sur-
rounding structures or because of disseminated disease.* Correspondence: j.sheringham@ucl.ac.uk
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unless otherwise stated.Despite the availability of high quality imaging including
helical computed tomography (CT scanning), endoscopic
ultrasound (EUS), and magnetic resonance imaging
(MRI), 25% to 40% of patients who undergo laparotomy
for pancreatic head cancer/periampullary cancer could
not be resected, with non-resectability identified only
during laparotomy [6,7].
A recent Cochrane Review of 15 studies and a total of
1015 patients found that diagnostic laparoscopy prior to
laparotomy can decrease the rate of unnecessary laparot-
omy from 40% to 17% in patients with pancreatic and
periampullary cancer found to have resectable disease
from a CT scan [8]. Diagnostic or staging laparoscopy isThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by high quality imaging techniques such as CT scanning.
The Cochrane Review included only studies in which bi-
opsy confirmation of metastatic spread was obtained.
The specificity of diagnostic laparoscopy in all studies
was 1, since the review included only studies in which
diagnostic laparoscopy along with biopsy confirmation
of metastatic spread was used as the index test. A review
of the NHS Economic Evaluations Database [9] using the
search term (laparoscop*) AND ((pancrea*) OR (periam-
pull*)) [28 August 2013] identified 31 studies, but none of
these evaluated diagnostic laparoscopy in patients who
were resectable following CT scanning. This study investi-
gates the cost-effectiveness of diagnostic laparoscopy prior
to laparotomy versus direct laparotomy in patients with
pancreatic and periampullary cancer who were considered
to have resectable disease and be suitable for major
surgery following CT scanning.
Methods
This is a model-based cost-utility analysis to estimate
the mean cost per patient and the mean outcome per
patient associated with diagnostic laparoscopy prior to
laparotomy versus direct laparotomy in patients with
pancreatic or periampullary cancers, found to have
resectable disease from a CT scan. In our base case we
assume that laparotomy following diagnostic laparoscopy
occurs in a subsequent admission, and therefore if the
laparotomy is unnecessary there is a cost saving because
use of the operating theatre and the hospital stay are
avoided. In a sensitivity analysis we consider a situation
where the laparotomy is undertaken in the same admis-
sion as the diagnostic laparoscopy. In this case we
assume the cost saving is smaller because while the hospital
stay is avoided the cost of the operating theatre would
still be incurred if the laparotomy is cancelled.
The outcome measure is quality-adjusted life years
(QALYs), which combine length of life and quality of life
[10]. QALYs are the recommended outcomes for use in
economic evaluations in the UK as they are a common unit
that allow for comparable decisions about resource alloca-
tion across different health conditions. The analysis is
undertaken from the perspective of the UK National Health
Service (NHS). Costs are calculated in 2011/12 UK£. Since
diagnostic laparoscopy is unlikely to affect long term dis-
ease outcomes, a time horizon of six months for costs and
outcomes was considered to be appropriate. This is suffi-
ciently long to capture the negative impact of laparotomy
on quality of life [11-13]. Due to the short time horizon,
discounting of costs and benefits was unnecessary.
Model structure
The analysis uses a decision tree to describe the options
being compared and the possible pathways followingthem (Figure 1). This is a commonly used approach in
cost-effectiveness studies of health care programmes
[10]. The nodes of a decision tree are points where more
than one event is possible. The branches are mutually
exclusive events following each node. Decision nodes,
represented by squares, show the different options that
might be chosen by decision-makers based on the costs
and benefits they produce (e.g., to choose diagnostic
laparoscopy or direct laparotomy). Chance nodes, repre-
sented by circles, show uncertain events, each of which
is associated with a probability that it will occur (e.g.,
whether the diagnostic laparoscopy will show that the
cancer is resectable or not). Terminal nodes, represented
by triangles, are the endpoints of a decision tree, beyond
which no further pathways are available. Each terminal
node has costs and QALYs associated with it, summaris-
ing the sequence of decisions and events on a unique
path leading from the initial decision node to that ter-
minal node. These costs and QALYs are expected values,
based on the probability of each event on the pathway
occurring up to that point and the costs and QALYs
associated with each event.
Patients enter the model with pancreatic or periam-
pullary cancer that has been identified as being resect-
able following CT scanning. If they undergo diagnostic
laparoscopy this may be adequate for determining
resectability if histologic confirmation of metastatic
disease is possible. If the diagnostic laparoscopy is ad-
equate then it will indicate whether or not the tumour
is resectable and if it is, the patient will have a laparot-
omy. During the laparotomy the tumour may be
resected or not. If it is not resected, the patient receives
palliative treatment. The laparotomy may result in com-
plications, in some cases an additional laparotomy may
be required to treat the complications, and the patient
may die perioperatively. If the laparoscopy identifies the
tumour as not being resectable then curative surgery is
not undertaken and the patient will receive palliative
treatment.
For patients undergoing direct laparotomy, it was
assumed that the pathway was the same as for resectable
disease being identified after adequate laparoscopy, but
the probabilities, costs and QALYs associated with each
pathway may be different. If the diagnostic laparoscopy
was inadequate for histologic confirmation of metastatic
disease, the diagnostic laparoscopy was considered to be
non-informative and the subsequent pathway was
assumed to be as for direct laparotomy but also incur-
ring the costs of the diagnostic laparoscopy procedure.
Probabilities
The probabilities associated with mutually exclusive events
at each chance node were obtained from published
sources (Additional file 1) [8,14,15]. The probability of
Figure 1 Decision tree model structure.
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0.403, calculated in the Cochrane Review as the median
pre-test prevalence after CT scan of unresectable dis-
ease due to distant metastases or local infiltration [8].
Values in the individual studies included in the
Cochrane Review ranged from 0.17 to 0.82 [8]. The
Cochrane Review also calculated a post-test probability
of unresectable disease of 0.173 (95% CI 0.12 to 0.24),
meaning that if a patient is said to have resectable
disease after diagnostic laparoscopy, there is a 0.173
probability that their cancer will be unresectable. The
difference in the probability that the tumour is un-
resectable following adequate diagnostic laparoscopy
compared with direct laparotomy is therefore 0.403-
0.173 = 0.230, meaning that on average using diagnostic
laparoscopy prior to laparotomy would avoid 230 un-
necessary laparotomies in 1000 patients in whom lapar-
otomy is planned for curative resection of pancreatic
cancers [8] and 770 patient would have a laparotomy.
The probability of undergoing laparotomy is 1–0.230 =
0.770, and the probability the tumour is unresectable
among those who have a laparotomy is 0.173/0.770 =0.225. Put another way, with direct laparotomy, 403
patients in 1000 would have unresectable disease. With
diagnostic laparoscopy 230 of these patients would
avoid an unnecessary laparotomy, 770 would have a
laparotomy and 770*0.225 = 173 of these would have
unresectable disease. The probabilities of complications
with laparotomy, of relaparotomy, and of perioperative
death were taken from a cohort study of 366 patients
with pancreatic cancer [14]. The probability of inad-
equate laparoscopy was taken from one of the studies
included in the Cochrane Review which reported this
information [15].
Outcomes
QALYs combine length of life and quality of life, where
the latter is measured by utility scores. A utility score of
1 represents full health and a utility of 0 death; negative
values represent states worse than death. A review of the
NHS Economic Evaluations Database [9] was under-
taken using the search terms (pancrea* OR ampullary
OR periampullary) AND (QALY) [23 February 2014] to
identify studies reporting relevant utility scores. After
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removing duplicates, 5 studies containing potentially
relevant utility data were identified [16-20]. The utility
scores used in the model were from one study [19],
selected because values were presented for different
points over time, because utility scores for all the health
states in the model were included in this study enabling
better comparability between values, and the values re-
ported also reflected trends in disease-specific quality of
life measures found in other studies [11-13] (Additional
file 1). Utility scores were measured at 2 weeks, 3 months
and 6 months. QALYs were estimated using the trapez-
ium rule for calculating the area under the curve.
Costs
The cost of diagnostic laparoscopy, including histological
examination of tissue obtained at laparoscopy was assumed
to be £995 (Additional file 1) [21]. This is the average value
of the elective inpatient and day case cost, weighted by the
proportion of patients in each group. Surgical resection
with and without complications was assumed to cost £12
006 and £7083, respectively [21]. Laparotomy without re-
section was assumed to cost £5378 with complications and
£4487 without complications [21]. The cost of repeat lapar-
otomy was assumed to be £7083 [21].
Measuring cost-effectiveness
Cost-effectiveness was measured using monetary net
benefits (MNBs). For each treatment the MNB was
calculated as the mean QALYs per patient accruing to
that treatment multiplied by decision-makers’ maximum
willingness to pay for a QALY (also referred to as the
cost-effectiveness threshold, which in the UK is approxi-
mately £20 000 to 30 000 per QALY gained [22]), minus
the mean cost per patient for the treatment. This
approach converts the outcomes from each treatment
into monetary terms and then subtracts the costs of
each treatment from the monetised benefits, calculating
the net benefit of each treatment in monetary terms.
MNBs were calculated using the base case parameter
values shown in Additional file 1; these are referred to as
the deterministic results since they do not depend on
chance. The treatment with the highest MNB represents
good value for money and is preferred on cost-effectiveness
grounds.
Sensitivity analyses
One-way sensitivity analysis was undertaken, varying the
probabilities, outcomes and costs one at a time within
the ranges listed in Additional file 1. The aim was to
identify the threshold value for each parameter, where
one exists, where the treatment with the highest MNB
changed (e.g., the value at which diagnostic laparoscopy
was no longer the most cost-effective option).We undertook a probabilistic sensitivity analysis (PSA)
as recommended by the National Institute for Health
and Care Excellence (NICE) [22]. Distributions were
assigned to parameters (Additional file 1) to reflect the
uncertainty with each parameter value. A random value
from the corresponding distribution for each parameter
was selected. This generated an estimate of the mean
cost and mean QALYs and the MNB associated with
each treatment. This was repeated 5000 times and the
results for each simulation were noted. The mean costs,
QALYs and MNBs for each treatment were calculated
from the 5000 simulations; these are referred to as the
probabilistic results since they depend on chance. Using
the MNBs for each of the 5000 simulations the proportion
of times each treatment had the highest MNB was calcu-
lated for a range of values for the maximum willingness to
pay for a QALY. These were summarised graphically using
cost-effectiveness acceptability curves [10].
In the PSA we used beta distributions to model uncer-
tainty in the probabilities and utility scores, and gamma
distributions to model uncertainty in costs [23]. In cases
where standard errors were required for the PSA and
these were not reported in the sources used it was as-
sumed the standard error was equal to the mean [23].
For the probability of unresectable disease with direct
laparotomy after CT scanning, the parameter values for
the beta distribution were based on the numbers of
unresectable and resectable cancers pooled across all
studies included in the Cochrane Review. For the post-
test probability of unresectable disease the parameter
values were calculated from the 95% confidence interval
reported in the Cochrane Review. For the utilities the
variance was calculated assuming a beta distribution
based on 97 observations [19,20]. 95% confidence inter-
vals around the base case values were derived using
standard deviations calculated from the 5000 simulations
in the PSA.
We undertook a further sensitivity analysis to investi-
gate the cost savings associated with diagnostic laparos-
copy. We considered a situation where the laparotomy
following diagnostic laparoscopy was scheduled for the
same admission as the diagnostic laparoscopy. When the
diagnostic laparoscopy indicated the tumour was not
resectable, so the laparotomy was not required, the cost
of the hospital stay was avoided but the cost of the oper-
ating theatre time was not. This was assumed to cost
£3524, based on 4 hours of theatre time at £881 per
hour [24].
Finally, because of jaundice being a relative early pres-
entation of ampullary cancers, the resectability rate of
ampullary cancers are believed to be higher than that of
pancreatic cancers [25]. We therefore reran our analyses
separately based on studies from the Cochrane Review
that included only patients with pancreatic cancer and
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the Cochrane Review, for patients with pancreatic cancer
the sensitivity of diagnostic laparoscopy was 67.9%, the
median pre-test probability of unresectability was 0.400
and the post-test probability of unresectable disease after
negative diagnostic laparoscopy was 0.180. One study in
the Cochrane Review included only patients with peri-
ampullary cancer [15]. In this study of 144 patients the
sensitivity of diagnostic laparoscopy was 52.0%, the pre-
test probability of unresectability was 0.174 and the
post-test probability of unresectable disease after nega-
tive diagnostic laparoscopy was 0.092. We reran our
models using these two sets of values holding all other
values constant.Results
Using base case values, and assuming laparotomy fol-
lowing diagnostic laparoscopy occurs in a subsequent
admission, diagnostic laparoscopy prior to resection in-
curred similar costs as proceeding straight to laparotomy
without prior laparoscopy (mean cost per patient £7470
(95% CI £7215 to £7724) versus £7480 (95% CI £7219 to
£7741) (Table 1); the cost of the diagnostic laparoscopy
(£995) was offset by avoiding the costs of unnecessary
laparotomy. QALYs up to 6 months were higher for
diagnostic laparoscopy compared with direct laparotomy
(mean QALYs per patient 0.346 (95% CI 0.346 to 0.347)
versus 0.337 (95% CI 0.337 to 0.338)) due to the negative
impact of unnecessary laparotomy.
The MNB for diagnostic laparoscopy prior to laparotomy
was significantly higher than those for direct laparotomy at
a maximum willingness to pay for a QALY of £30 000
(£2921 (95% CI £2807 to £3035) versus £2633 (95% CI
£2516 to £2750)) but at a willingness to pay for a QALY of
£20 000 the MNB for diagnostic laparoscopy was nume-
rically higher but the 95% CIs overlapped. As expected, the
probabilistic results (not shown) were numerically similar
to the deterministic results.Table 1 Base case results
Diagnostic laparoscopy Direct laparotomy
Costs 7470 (7356, 7583) 7480 (7363, 7597)
QALYs 0.346 (0.346, 0.347) 0.337 (0.337, 0.338)
Monetary net benefit
£20 000 −543 (−429, −656) −738 (−621, −855)
£30 000 2921 (2807, 3035) 2633 (2516, 2750)
QALY = quality adjusted life year. Costs are in 2011/12 UK£. Figures are expected
values per patient with 95% confidence intervals in brackets. The point estimates
are calculated using base case values of the model parameters (deterministic
results). The 95% confidence intervals are derived using standard deviations
calculated from the 5000 simulations in the probabilistic sensitivity analysis. The
monetary net benefit is calculated at a maximum willingness to pay for a QALY of
£20 000 and £30 000. The results are calculated using base case values of the
model parameters. Numbers may not sum due to rounding.In the one-way sensitivity analysis the results were
sensitive to changing the values of probability of non-
resectable disease with direct laparotomy: values in the
individual studies included in the Cochrane Review
ranged from 0.17 to 0.82 [8]; for values <0.36 direct
laparatomy had the highest MNB. Results were also sen-
sitive to the post-test probability of unresectable disease:
the Cochrane review calculated that the 95% CI of this
probability was 0.12 to 0.24 [8]; at values > 0.22 direct
laparatomy had the highest MNB.
The cost-effectiveness acceptability curves for each
treatment show that diagnostic laparoscopy prior to lapar-
otomy had a 63.2% probability of being cost-effective at a
maximum willingness to pay for a QALY of £20 000 and a
66.2% probability at a value of £30 000 (Figure 2).
When laparotomy was scheduled for the same admis-
sion as diagnostic laparoscopy, and the cost of the hospital
stay was avoided if the tumour was unresectable but the
cost of the operating theatre time was not, the costs
avoided by unnecessary laparotomy were smaller and the
mean cost per patient of diagnostic laparoscopy prior to
resection increased from £7470 to £8224, which was
higher than the cost of direct laparotomy. The MNB for
diagnostic laparoscopy prior to laparotomy was lower than
the MNB for direct laparotomy at a willingness to pay for
a QALY of both £20 000 and £30 000 (−£1297 versus
-£738 and £2167 versus £2633, respectively).
When we reran our analyses separately for subgroup
of studies from the Cochrane Review that included only
patients with pancreatic cancer the MNB for diagnostic
laparoscopy prior to laparotomy was higher than the MNB
for direct laparotomy at a willingness to pay for a QALY of
both £20 000 and £30 000 (−£607 versus -£751 and £2853
versus £2621, respectively). When we reran our analyses
separately for patients with periampullary cancer the MNB
for diagnostic laparoscopy prior to laparotomy was lower
that for direct laparotomy (−£2263 versus -£1693 and
£1197 versus £1734, respectively).
Discussion
Main findings
We estimated the mean cost per patient and the mean
outcome per patient associated with diagnostic lapa-
roscopy prior to resection versus direct laparotomy in
patients with pancreatic and periampullary cancer found
to be resectable with curative intent following CT scan-
ning. Diagnostic laparoscopy incurred the same overall
costs as direct laparotomy (mean cost per patient £7470
versus £7480) and QALYs up to 6 months were slightly
higher for diagnostic laparoscopy (mean QALYs per
patient 0.346 versus 0.337) due to the avoidance of
unnecessary laparotomy in patients with unresectable
disease. The MNBs for diagnostic laparoscopy prior to
resection were significantly higher than those for direct
Figure 2 Cost-effectiveness acceptability curves. The acceptability curves show the probability that each option is cost-effective at different
values of the maximum willingness to pay for a quality adjusted life year (QALY).
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QALY of £30 000 but not £20 000. There is some uncer-
tainty with this finding, with the results being sensitive
to key model parameters for test accuracy (probability of
unresectable disease (with curative intent) following CT
scan that shows resectable disease, post-test probability
of unresectable disease).
Diagnostic laparoscopy can either be performed as a
separate procedure or immediately prior to laparotomy
as part of larger procedure. The advantage of performing
diagnostic laparoscopy as part of a larger procedure are
that the patient needs only one hospital admission and
one general anaesthetic. However if the patient is diag-
nosed as having unresectable disease at laparoscopy and
the subsequent laparotomy is then cancelled, it means
that operating time is wasted. If laparoscopy is per-
formed as a separate diagnostic procedure, the patient
must undergo the burden of two separate hospital ad-
missions, time to surgery is delayed, which may increase
the probability of unresectable disease, and anaesthetics
but no operating time will be wasted if they are found to
have unresectable disease. When laparotomy is under-
taken in the same admission as diagnostic laparoscopy
and the cost of the hospital stay is avoided but the cost
of the operating theatre time is not, the costs of diagnos-
tic laparoscopy are higher than those for direct laparot-
omy and the MNBs are lower. Diagnostic laparoscopy is
not cost-effective in this scenario.
Diagnostic laparoscopy prior to laparotomy was cost-
effective among patients with pancreatic cancer. It was
not cost-effective in patients with periampullary cancerdespite decreasing the unresectability from 17.4% to
9.2%. This subgroup analysis is based on a single study.
One possible explanation of the finding is that fewer
periampullary cancer patients had unresectable disease
after a CT scan – 17.4% patients [15] compared to 40.0%
patients [8]. As indicated in the one-way sensitivity ana-
lysis, the results of cost-effectiveness were sensitive to
the proportion of patients with unresectable disease after
a direct laparotomy. Since fewer unnecessary laparo-
tomies were performed in patients with periampullary
cancer, diagnostic laparoscopy may not be cost-effective.
However, this has to be confirmed by other studies
investigating the incidence of unresectability after direct
laparotomy in patients with periampullary cancer or by
further studies investigating the utility of diagnostic
laparoscopy in patients with periampullary cancer.
Strengths and weaknesses
The strengths of this study are that it was based on a
recently published Cochrane review that analysed in
detail the available evidence for the diagnostic accuracy
of laparoscopy following CT scanning for assessing re-
sectability in pancreatic and periampullary cancer.
An extensive sensitivity analysis has also been per-
formed, which has been useful to show that the conclu-
sions are sensitive to key model parameters surrounding
test accuracy.
The main weakness of this study is that while the base
case values show diagnostic laparoscopy is cost-effective,
the sensitivity analysis indicates that the conclusions will
change if key model parameters vary within feasible
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effectiveness of diagnostic laparoscopy ought to be
treated with caution and further research is recom-
mended to assess cost-effectiveness in different set-
tings. This ought to account for the sensitivity and
specificity of diagnostic laparoscopy, the proportion of
people unresectable after direct laparotomy, and the
costs of laparotomy and diagnostic laparoscopy.
For simplicity the model has a time horizon of
6 months and only perioperative deaths are included.
The underlying mortality rate in patients with pancreatic
and periampullary cancer would affect both treatment
arms equally, and since we are interested in differences
in costs and outcomes between the two treatment arms
changing the underlying mortality rate would have no
impact on relative cost-effectiveness.
The costs associated with diagnostic laparoscopy prior
to laparotomy versus direct laparotomy were the same;
the QALY gains associated with diagnostic laparoscopy
prior to laparotomy are statistically significantly different
from zero, but small (mean QALY gain per patient 0.346
- 0.337 = 0.009). This difference may be less than the
minimal clinically important difference (minimal clinic-
ally important differences in health state utility values
are typically in the range 0.010 to 0.048) [26]. Hence,
any gains from diagnostic laparoscopy prior to laparot-
omy purely in terms of QALYs may be misplaced.
Comparison with other studies
This is the first study to evaluate the cost-effectiveness of
diagnostic laparoscopy prior to laparotomy versus direct
laparotomy in patients with pancreatic and periampullary
cancer who were resectable following CT scanning.
Implications for policy and practice
The implications of this study are that when laparotomy
following diagnostic laparoscopy occurs in a subsequent
admission, diagnostic laparoscopy appears to be cost-
effective in decreasing unnecessary laparotomy in patients
with pancreatic cancer (but not in those with periampul-
lary cancer) found to have resectable disease on CT scan,
producing a small improvement in health outcomes at no
extra cost. Diagnostic laparoscopy with laparotomy under-
taken in the same admission is not cost-effective.
The results are sensitive to the probability of unresect-
able disease (with curative intent) following CT scan that
shows resectable disease and the accuracy of diagnostic
laparoscopy. Given that both of these are operator
dependent and the probability of unresectable disease
(with curative intent following CT scan) may be lower in
patients with periampullary cancer, it is recommended
that these probabilities are studied over a period of time
to ensure that the most cost-effective option is chosen in
that particular setting.Advances in imaging techniques such as refinements
to CT, MRI or positron emission tomography (PET)
scans alone or in combination may provide greater diag-
nostic sensitivity and specificity in pancreatic cancer.
However, at present, MRI and PET scans are not as
widely available or performed as CT scans and diagnos-
tic laparoscopy and there is currently no evidence that
MRI and PET scans decrease unresectability rates. The
cost-effectiveness of diagnostic laparoscopy therefore
should be revisited if there is evidence that refined CT
scanning methods or routine MRI or PET scanning
shows a reduction in unresectability rates.
Further research
This study is based on a Cochrane review of the diagnostic
accuracy of laparoscopy following CT scanning for asses-
sing resectability in pancreatic and periampullary cancer.
The review concluded that further diagnostic test accuracy
studies with low risk of bias should be undertaken to
calculate the utility of diagnostic laparoscopy more accur-
ately. Given that the results in this study are sensitive to
key model parameters for test accuracy, this research
would also be beneficial for estimating whether or not
diagnostic laparoscopy is cost-effective.
Further research would be useful to consider the impact
that avoiding unnecessary laparotomies would have on
freeing up operating theatre time and hospital beds if diag-
nostic laparoscopy was implemented into routine practice.
Conclusions
Diagnostic laparoscopy in patients with CT resectable
pancreatic and periampullary cancer appears to be cost-
effective when laparotomy following diagnostic laparos-
copy occurs in a subsequent admission.
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